Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week High - Here's What Happened

Key Points

• Dianthus Therapeutics (NASDAQ:DNTH) achieved a new 52-week high of $32.80, trading at $31.80 with a volume of over 5.9 million shares, compared to a previous close of $26.50.
• Equities analysts have given the stock an average rating of "Buy" with a consensus price target of $54.00, while individual targets range from $40.00 to $42.00 following recent upgrades.
• The company reported a net loss of ($0.88) earnings per share for the last quarter, missing consensus estimates, and anticipates posting an earnings per share of -2.61 for the current year.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $32.80 and last traded at $31.80, with a volume of 5962054 shares trading hands. The stock had previously closed at $26.50.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DNTH shares. William Blair initiated coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating for the company. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday. Robert W. Baird decreased their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Finally, Wedbush increased their price target on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $54.00.

Dianthus Therapeutics Price Performance

The stock's 50 day simple moving average is $21.54 and its two-hundred day simple moving average is $20.09. The firm has a market cap of $1.02 billion, a P/E ratio of -9.78 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DNTH. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $27,000. US Bancorp DE grew its holdings in shares of Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after buying an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at approximately $59,000. GAMMA Investing LLC grew its holdings in shares of Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after buying an additional 3,317 shares during the last quarter. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.